KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite for Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active